
## Shinichirio Ueda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7398949/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002051.	3.9	57
2	Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Medicine, 2020, 17, e1003095.	3.9	57
3	Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. International Journal of Cardiology, 2019, 281, 35-39.	0.8	52
4	Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. International Journal of Cardiology, 2018, 253, 161-166.	0.8	51
5	Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovascular Diabetology, 2016, 15, 87.	2.7	28
6	Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. Cardiovascular Drugs and Therapy, 2018, 32, 73-80.	1.3	20
7	Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovascular Diabetology, 2020, 19, 89.	2.7	20
8	Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial. Scientific Reports, 2019, 9, 8537.	1.6	12
9	Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. Cardiovascular Diabetology, 2019, 18, 158.	2.7	12
10	Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertension Research, 2022, 45, 106-115.	1.5	10
11	Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2020, 11, 575557.	1.5	7
12	Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial. RMD Open, 2022, 8, e002226.	1.8	6
13	<p>Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4993-5001.	1.1	5
14	Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of Atherosclerosis and Thrombosis, 2020, 29, .	0.9	4
15	Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized) Tj ETQq1 1 0.7 Iournal of Clinical Medicine, 2020, 9, 93.	′84314 rg 1.0	BT_/Overloc
16	Endosonographic finding of the simultaneous depiction of bile and pancreatic ducts can predict difficult biliary cannulation on endoscopic retrograde cholangiopancreatography. PLoS ONE, 2020, 15, e0235757.	1.1	1
17	Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 685-694.	1.1	0

